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ProteasomeMultidrug resistance-associated protein 2 (MRP2) is amember of a family of efﬂux transporters that are involved in
biliary excretion of organic anions from hepatocytes. Disrupted canalicular localization and decreased protein ex-
pression of MRP2 have been observed in patients with chronic cholestatic disorder and hepatic failure without a
change in its mRNA expression. We have previously demonstrated that post-transcriptional regulation of the
rapid retrieval of ratMRP2 from the canalicularmembrane to the intracelluar compartment occurs under conditions
of acute (~30 min) oxidative stress. However, it is unclear whether MRP2 expression is decreased during its sus-
tained internalization during chronic oxidative stress. The present study employed buthionine sulfoximine (BSO)
to induce chronic oxidative stress in the livers of Sprague–Dawley rats and then examined the protein expression
and localization of MRP2. Canalicular MRP2 localization was altered by BSO treatment for 2 h without changing
the hepatic protein expression of MRP2. While the 8 h after exposure to BSO, hepatic MRP2 protein expression
was decreased, and the canalicular localization of MRP2 was disrupted without changing the mRNA expression of
MRP2. The BSO-induced reduction in MRP2 protein expression was suppressed by pretreatment with N-
benzyloxycarbonyl (Cbz)-Leu-Leu-leucinal ( MG-132), a proteasomal inhibitor. Furthermore, the modiﬁcation of
MRP2 by small ubiquitin-relatedmodiﬁer 1 (SUMO-1)was impaired in BSO-treated rat liver,while that by ubiquitin
(Ub) and MRP2 was enhanced. Taken together, the results of this study suggest the sustained periods of low GSH
content coupledwith alteredmodiﬁcation ofMRP2 by Ub/SUMO-1were accompanied by proteasomal degradation
of MRP2.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Cholephilic compounds are excreted into the bile by distinct ATP-
dependent primary active transporters located at the canalicular
membrane. Of these, multidrug resistance-associated protein 2 (rat:
rMRP2 and human: hMRP2) is of paramount importance. In humans,
biliary excretion of organic anions (e.g., bilirubin glucuronides, re-
duced glutathione (GSH), and GSH conjugates) is mediated by
MRP2, a conjugate export pump encoded by the MRP2 gene [1].recruitment domain; BSA, bo-
; BSO, buthionine-sulfoximine;
DJS, Dubin-Johnson syndrome;
ate dehydrogenase; γ-GCS, γ-
gh performance liquid chroma-
sistance-associated protein 2;
, PSD95/Dlg/ZO1-containing 1;
iﬁer; t-BHP, tert-butyl hydro-
itin; UBA2, ubiquitin-activating
+81 43 226 2886.
l rights reserved.Several disorders are associatedwithdeﬁcient canalicular localization/
expression ofMRP2. For example, Dubin–Johnson syndrome (DJS) is a he-
redity disease characterized by conjugated hyperbilirubinemia. The deﬁ-
cient hepatobiliary transport of anionic conjugates results from the
absence of a functionalMRP2 in the canalicularmembraneof hepatocytes.
A number of mutations in the hMRP2 gene have been identiﬁed in pa-
tients with DJS. Certain DJS mutations (e.g., missence mutations R768W
and I1173F; deletion mutation R1392, M1393) have been reported to
cause defects in canalicular sorting and rapid proteasomal degradation
of the hMRP2 protein [2–4]. In addition to the inherited abnormality of
canalicular hMRP2 expression, it was reported that canalicular hMRP2 lo-
calization andoverall cellular expression of hMRP2proteinwas decreased
without changing its mRNA level in patients with chronic liver failure
(primary biliary cirrhosis and hepatitis C virus infection) [5,6] Notably,
the presence of oxidative stressmarkerswas correlatedwith chronic cho-
lestatic disorder in these liver disease patients [7].
We have previously demonstrated that rMRP2 internalization from
the canalicularmembrane to the intracellular compartment occurswithin
a few minutes after ethacrynic acid (EA) treatment, tert-butyl
hydroperoxide (t-BHP) treatment, or within 2 h after lipopolysaccharide
(LPS) treatment [8–11]. Similar phenomenon was also conﬁrmed for
hMRP2 using liver slices [12]. All these events seem to be triggered by a
981S. Sekine et al. / Biochimica et Biophysica Acta 1822 (2012) 980–987decrease of GSH in the hepatocytes. Based on our line of previous exper-
iments using isolated rat hepatocyte culture model, we proposed that
GSH decrease causes intracellular Ca2+ elevation, NO release and ﬁnally
leads to PKC activation [9]. Then, interaction of rMRP2 with radixin, a
cytoskeltal linker protein connecting rMRP2 to the ﬁlamentous actin,
was decreased as a result of dephosphorylation of radixin [22]. We also
demonstrated that once decreased rMRP2 surface expression induced
by t-BHPwas recovered to the control level by the replenishment of intra-
cellularGSHwithin anhour [10]. On the other hand, only limited informa-
tion is available on the fate of rMRP2 under sustained GSH decrease
condition; i.e. stably pooled in the intracellular compartment to be
recycled back to the cell surface or directed to degradation pathway.
Ubiquitination is a regulated post-translational modiﬁcation that
conjugates ubiquitin (Ub) to the lysine residues of target proteins,
thereby determining their intracellular fate. The canonical role of ubi-
quitination is to mediate the proteasomal degradation of proteins that
carry a single Ub molecule or a polymeric chain of Ub molecules on a
speciﬁc lysine residue. Several proteins (transglutaminase 2 and apo-
ptosis repressor with caspase recruitment domain (ARC)) are known
to be degraded by ubiquitination during oxidative stress [14]. Recently,
experiments employing the yeast-two hybrid screening demonstrated
that small ubiquitin-like modiﬁer (SUMO)-related enzymes and mole-
cules, including ubiquitin-activating enzyme 2 (UBA2) and ubiquitin-
conjugating enzyme 9 (Ubc9), interacted with the linker regions of rat
and human MRP2 [15]. Moreover, modiﬁcation of rMRP2 by SUMO-1
was conﬁrmed (an isoform of the SUMO family member), and rMRP2
protein expression was decreased in Ubc9 knock-down rat hepatoma
cells [15]. Although the fundamental role of SUMO has not yet been
completely elucidated, it has been established that SUMO competes
with Ub for modiﬁcation of the same lysine residue in target proteins.
In this manner, SUMO protects proteins from the Ub/proteasome-
dependent degradation pathway [16–18].
The current study was designed to evaluate the hypothesis that
SUMO-1/Ub-mediated modiﬁcations of rMRP2 are key factors that
regulate the fate of rMRP2 during sustained GSH decreased condition.
To examine this possibility, Sprague–Dawley rats were treated with
buthionine-sulfoximine (BSO), an inhibitor of γ-glutamyl cysteine
synthetase (γ-GCS). γ-GCS is a rate-limiting enzyme in the synthesis
of GSH and as such, its inhibition can cause long-lasting GSH depletion
for at least 8 h, which is longer than our previous experimental condi-
tion. The results of this study indicate that rMRP2 protein is
internalized at early phase as reported previously and subsequently
degraded at later phase in a proteasome-dependent manner if GSH(A) (B)
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Fig. 1. Effect of BSO treatment on hepatic rMRP2 protein and mRNA expression. Rats were gi
levels were measured by real-time RT-RCR. rMRP2 mRNA levels were normalized to GAPDH
to immunoblot analysis with anti-MRP2 antiserum. The relative densities of the rMRP2 ban
saline-treated control value. Results are given as the mean±S.D. (n=4 independent rat livdecease is sustained for a while (8 h). Ubiquitination and SUMOylation
of rMRP2 may have a role in determining its fate after internalization.
2. Materials and methods
2.1. Chemicals and reagents
BSO, o-phthalaldehyde, 2-mercaptoethanol, and triﬂuoroacetic acid
were obtained from Wako Pure Chemical Industries, Ltd. (Osaka,
Japan). N-benzyloxycarbonyl (Cbz)-Leu-Leu-leucinal (MG-132) was
obtained from Calbiochem (Darmstadt, Germany), and 3-
ﬂuorotyrosine was obtained from Tokyo Kasei Chemical Industry Co.,
Ltd. (Tokyo, Japan). Rabbit anti-MRP2 antiserum was raised against
the 12-amino acid sequence at the carboxyl terminus of rat rMRP2
[19]. Mouse monoclonal antibody against MRP2 (M2III6) was obtained
from Chemicon International, Inc. (Temecula, CA). Monoclonal mouse
antibody (FK2) against mono- and poly-ubiquitinated conjugates was
obtained from Enzo Life Sciences, Inc. (Plymouth, PA). Puriﬁed mouse
anti-rat cluster of differentiation 26 (CD26; OX-61) and mouse mono-
clonal anti-β-actin antibodies were obtained from Sigma-Aldrich Che-
micals (St. Louis, MO). Rabbit polyclonal anti-SUMO-1 and SUMO-2/3
antibodies and horseradish peroxidase-conjugated secondary anti-
bodies were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). All
other chemicals and solvents were of analytical grade.
2.2. Animals
Male Sprague–Dawley rats (Japan SLC Inc., Shizuoka, Japan), 6 to
7 weeks of age andweighing 170 to 220 g, were used for all experiments.
The animalswere treatedhumanely in accordancewith the “Guide for the
Care and Use of Laboratory Animals” issued by the National Institutes of
Health (Bethesda,MD). In addition, all protocolswere approvedby the In-
stitutional Animal Care and Use Committee of Chiba University.
2.3. Experimental model
The rats were divided into two groups that each consisted of four
to ﬁve rats. Experimental animals were given an intraperitoneal (i.p.)
injection of BSO (1 mg/kg). Control animals were injected with saline
instead of BSO. The rats were sacriﬁced 2, 8, or 24 h after BSO or saline
injection, and the livers were harvested. In some experiments, the
proteasome inhibitor MG-132 (0.5 mg/kg i.p.) was injected 1 h before
BSO or saline treatment.(C)
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Fig. 2. Effect of BSO treatment on thedistribution of rMRP2 and radixin in the rat liver. Immunoﬂuorescence analysis confocal laser scanningmicroscopyof the rat liver. Frozen sections (6 μm
in thickness) of acetone-ﬁxed tissue were stained with anti-MRP2 (green) and anti-phosphorylated ezrin (Thr567)/radixin (Thr564)/moesin (Thr558) (p-ERM) antibody (red) antibodies
and examined with a confocal laser microscope.
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Liver samples were mixed with 3-ﬂuorotyrosine as an internal
standard followed by ﬁltration through a 0.45-μm syringe ﬁlter
(Millex-LH; Millipore Corp., Bedford, MA). High performance liquid
chromatography (HPLC) was performed as described previously
[20]. Brieﬂy, an Inertsil ODS column (4.6-mm inner diame-
ter×250 mm; GL Sciences Ltd., Tokyo, Japan) was used with the mo-
bile phase (0.1% triﬂuoroacetic acid to methanol ratio=20:1) at a
ﬂow rate of 1.0 ml/min. The eluate from the column was mixed
with a solution containing 1.86 mM o-phthalaldehyde and 1.71 mM
2-mercaptoethanol in 100 mM carbonate buffer (pH 10.5), which
was delivered at a rate of 0.2 ml/min. The mixture was then passed
through a stainless steel coil at 70 °C to facilitate derivatization of
GSH with o-phthalaldehyde. A ﬂuorescence detector was used and
operated at an excitation wavelength of 355 nm and an emission
wavelength of 425 nm. The concentration of GSH was calculated
with reference to the height of a standard GSH sample.
2.5. Crude membrane preparation
Liver specimens (1 g) were snap-frozen in liquid nitrogen. The
crude membrane (CrM) fraction was prepared as previously de-
scribed [21]. CrM fractions and crude liver homogenates were sub-
jected to immunoblot analysis, as described previously [8,9] and
elaborated upon, below.
2.6. Immunoblot analysis
Rat liver CrM fractions (5 μg protein) and homogenates (35 μg pro-
tein) were subjected to electrophoresis in a 8.5% polyacrylamide slab gel
containing 0.1% SDS and then transferred to an Immobilon-P TransferMembrane ﬁlter (Millipore Corp., Billerica, MA). The membrane was
blocked with TTBS (0.05% Tween 20/Tris-buffered saline) containing 3%
bovine serum albumin (BSA) for 2 h at room temperature or overnight
at 4 °C. Blotted proteins were probed with primary antibodies for 1 h at
room temperature or overnight at 4 °C. TTBS containing 0.1% BSA was
used to dilute the primary antibodies as follows: rabbit polyclonal antise-
rum against rat MRP2 [1:1000]; M2III6 anti-MRP2 antibody [1:1000];
rabbit polyclonal anti-SUMO-1 antibody [1:1000]; rabbit polyclonal
anti-SUMO-2/3 antibody [1:1000]; mouse monoclonal FK2 antibody
against mono- and poly-ubiquitinylated conjugates [1:1000]; and
mouse monoclonal anti-β-actin [1:2000]. The membrane was incubated
for 1 h at room temperature with horse radish peroxidase-conjugated
secondary antibodies that were diluted in TTBS containing 0.1% BSA. Im-
munoreactive proteins were detected using an enhanced chemilumines-
cence system (GE Healthcare, Little Chalfont, Buckinghamshire, UK) and
an LAS-1000 luminescent image analyzer (Fujiﬁlm, Tokyo, Japan).2.7. Semiquantitative real-time RT-PCR
Total mRNA was prepared from perfused rat liver using the RNA
Solve reagent (OMEGA Bio-tek, Inc., Doraville, GA). Reverse transcrip-
tion was performed with total RNA (0.4 μg) using a Takara RNA PCR
kit ver. 3.0 (Takarabio, Shiga, Japan). Real-time RT-PCR was per-
formed using the Power SYBR Green PCR Master Mix (Eurogentee
SA, Seraing, Belgium) to quantify the mRNA expression of rMRP2
(forward primer: 5′ tga tcg gtt tgc tga aga gct 3′; reverse primer: 5′
acg cac att ccc aac aca aa 3′) relative to glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) (forward primer: 5′ gtg gtg cca aaa ggg tca
3′; reverse primer: 5′ att tct cgt ggt tca cac cca 3′). Real-time RT-
PCR ampliﬁcation was determined utilizing an ABI Prism 7000 ma-
chine (Applied Biosystems, Foster City, CA).
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Frozen small liver blocks were embedded in Tissue-Tek O.C.T Com-
pound (Sakura Finetechnical Co. Ltd., Tokyo, Japan) and then used to pre-
pare 6-μm-thick sections at−25 °C, which were then ﬁxed in acetone at
room temperature for 10 min. The sections on the slideswere hydrated in
30 mMglycine containing phosphate-buffered saline (G-PBS) for 15 min.
Then they were incubated with mouse monoclonal anti-MRP2 antibody
M2III5 (Abcam, Cambridge, UK) (1:35) and rabbit anti-phosphorylated
ezrin (Thr567)/radixin (Thr564)/moesin (Thr558) (p-ERM) antibody
(Millipore Corp., Billerica, MA) (1:35) for 1 h. After rinsing with G-PBS,
the slides were incubated for 1 h with goat Alexa Fluor 546 anti-rat IgG
(1:150) and goat Alexa Fluor 488 anti-mouse IgG (1:150). The antibodies
were diluted in PBS containing 0.1% BSA. After rinsing with G-PBS, the
slides were dipped in TBS for 5 min and then the samples weremounted
in VECTASHIELD (Vector Laboratories, Burlingame, CA). Immunoﬂuores-
cence imaging was performed using a confocal laser scanning micro-
scope, LSM510 type (Carl Zeiss, Jena, Germany).
2.9. Immunoprecipitation analysis
Frozen liverswere homogenizedwith ten vertical strokes of a Teﬂon
homogenizer (DuPont, Wilmington, DE) in lysis buffer (1 ml/g tissue
wet weight) containing 25 mM Tris–HCl, pH 7.5, 5 mM EDTA, 250 mM
NaCl, 1% (v/v) Triton X-100, 60 mM n-octyl-β-D-glucopyranoside,
50 mM NaF, 1 mM Na3VO4, and protease inhibitor solution (1 mM
PMSF, 5 μg/ml leupeptin, and 1 μg/ml pepstatin A). Liver homogenates
were incubated with lysis buffer (25 μl/mg protein) for 1 h at 4 °C and
centrifuged at 20,630 g for 10 min. The supernatant was collected and
rotated overnight at 4 °C with protein G-conjugated magnetic beads
and anti-MRP2 antiserum (12 μl per 20 mg tissue homogenate protein).
The beads were collected by sedimentation at 9,170 g for 1 min and
washed three times with wash buffer containing 25 mM Tris–HCl, pH
7.5, 5 mM EDTA, 150 mM NaCl, 1% (v/v) Triton X-100, 50 mM NaF,
and 1 mM Na3VO4. Finally, elution buffer containing 10 mM Tris–HCl,
pH 6.5, 3% (w/v) SDS, 10% (v/v) glycerol, 5% (v/v) β-mercaptoethanol,
8 M urea, and 0.001% bromophenol blue was added, and the beads
were boiled at 95 °C for 5 min. The suspension was centrifuged, and
the supernatantwas subjected to SDS-polyacrylamide gel electrophore-
sis followed by immunoblot analysiswithM2III6 FK2, anti-SUMO-1, and
anti-SUMO-2/3 antibodies.
2.10. Statistical analysis
All data are represented as the mean±the standard deviation
(S.D.). Data were analyzed using the t-test (Figs. 1, 4, 5) and theBonferroni correction (Fig. 3). Differences between the means at the
level of pb0.05 were considered to be signiﬁcant.3. Results
3.1. The effect of BSO treatment on intrahepatic GSH content
Rats were given an i.p. injection of BSO (1 mg/kg body weight) to
selectively inhibit γ-GCS and establish a sustained decrease in hepatic
intracellular GSH content. Intrahepatic GSH content was evaluated at
2, 8, and 24 h after BSO or control saline injection to see how long the
GSH decrease continued. As shown in Table 1, GSH content in BSO-
versus saline-treated rats was signiﬁcantly decreased at 2 and 8 h.
The GSH content was 54.2% of the corresponding control value at
2 h and 17.2% of the corresponding control value at 8 h, but returned
to control levels at 24 h after BSO injection (Table 1). This result sug-
gests that GSH decrease was signiﬁcantly reduced at least for 8 h
under this experimental condition. Notably, it is substantially longer
than our previous experimental condition (~2 h) where total protein
expression of rMRP2 was not changed [8–11]. So, we now tried to
chase the fate of rMRP2 until 8 h after BSO treatment where GSH
decrease was still continued.3.2. Effect of BSO treatment on rMRP2 protein and mRNA expression
Previous work indicated that MRP2 localized at the canalicular
membrane was rapidly retrieved to the intracellular compartment
after EA, t-BHP, or LPS treatment, as reﬂected by the decrease
in GSH levels without changes in total rMRP2 protein or
mRNA expression [8–11]. Therefore, the current study similarly
evaluated rMRP2 protein and mRNA expression following BSO injec-
tion. At 2 h after treatment, neither the rMRP2 protein content nor
the rMRP2 mRNA level was decreased in the livers of BSO-injected
rats compared with the saline-injected controls. Hepatic rMRP2
mRNA and protein levels in BSO-injected rats were 114.5% and
106.2% of the values in saline-injected rats, respectively (Fig. 1A
and B). At 8 h after BSO treatment, protein expression of rMRP2 in
the liver was signiﬁcantly decreased, but mRNA expression was
unaltered. The protein and mRNA levels at 8 h were 77.2±2.1%
and 121.2±15.2% of saline-treated control values, respectively
(Fig. 1A and B). These data indicate that the rMRP2 protein was
degraded in a post-transcriptional manner, and that the degradation
was stimulated by a continuous GSH decrease during an 8 h
time period.
control BSO
IP:MRP2
IB
(A) (C)
control
BSO
200
300
400
0
100
Ub
iq
ui
tin
at
ed
 rM
RP
2/
rM
RP
2 
ra
tio
(%
 of
 co
nt
ro
l)
***
Anti-
ubiquitinated 
protein (FK2)
Anti-
ubiquitinated 
protein (FK2)
210 kDa
175 kDa
175 kDa
Rabbit serum IgG
IP:MRP2
rMRP2(M2III6)
IB
(B)
210 kDa
175 kDa
rMRP2(M2III6)
210 kDa
175 kDa
Fig. 4. Effect of BSO treatment on the modiﬁcation of rMRP2 by ubiquitination. (A) and (B) Rat liver lysates were subjected to immunoprecipitation (IP) using anti-MRP2 antiserum.
Immunoprecipitates derived from the livers of saline-treated (A) and BSO-treated (B) rats were then subjected to immunoblot (IB) analysis using monoclonal antibodies against
MRP2 (M2III6) and mono- and poly-ubiquitinylated conjugates (FK2). Rabbit serum IgG was used as a negative control in (A). (C) The band density of the ubiquitinated proteins
in (B) (represented by arrows) was normalized by the band density of rMRP2. The values are expressed as the percentage of saline-treated control. Results are presented as the
mean±S.D. (n=5 independently treated rat livers for each condition.) ***pb0.001 compared with control.
984 S. Sekine et al. / Biochimica et Biophysica Acta 1822 (2012) 980–9873.3. Effect of BSO treatment on the canalicular localization of rMRP2
As previously reported and noted above, canalicular rMRP2 localiza-
tion is strictly correlated with intracellular GSH content [10,22]. There-
fore, canalicular rMRP2 localization was investigated in BSO-treated rat
livers. At 2 and 8 h after BSO injection, a decrease in rMRP2 expression
was observed in the isolated CrM fraction. The rMRP2 expression at 2 h
was 78.9±2.8% of the control value in saline-treated rats, and further
reduced to 65.7±2.4% of the control value at 8 h (Fig. 1C). Hence,20
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treated rat livers for each condition.) *pb0.05 compared with control.canalicular rMRP2 was internalized as early as 2 h following BSO treat-
ment with no accompanying change in total hepatic rMRP2 expression
(Fig. 1A and B). The decreased canalicular rMRP2 expression at 8 h after
BSO treatment was apparently due to both the decrease in total rMRP2
protein expression (Fig. 1B) and the altered canalicular localization
(Fig. 1C).
Immunoﬂuorescence analysis of the liver treated with BSO sup-
ported these observation (Fig. 2). In control, rMRP2 colocalizes with
phosphorylated radixin along the canalicular membrane as reported
previously (reference 22). At 2 h after BSO treatment, colocalization
was decreased and diffuse rMRP2 staining was observed. At 8 h after
BSO treatment, overall rMRP2 ﬂuorescence intensity was weakened
compared to that in the sample at 2 h after BSO treatment.3.4. Role of the proteasomal degradation pathway
Most proteins undergo degradation through lysosomal and/or
proteasomal complexes. The proteasome inhibitor MG-132 is cell-
permeable and blocks proteasomal function, without affecting normal
biological processes such as ATP metabolism and protein synthesis
[23]. Because rMRP2 degradation was observed by virtue of the de-
cline in intrahepatic GSH content at 2 and 8 h following BSO treat-
ment, the dependence of rMRP2 protein degradation on the
proteasomal pathway was next investigated using an in vivo experi-
mental animal model.Table 1
Effect of BSO on intrahepatic GSH content (nmol/mg protein).
2 h 8 h 24 h
Control 28.4±2.3 26.2±2.5 27.2±1.4
BSO 15.4±1.5** 4.5±1.0*** 22.5±3.8
The results are given as the mean±S.D. of ﬁve rats. **pb0.01, ***pb0.001 compared
with the saline control.
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injected 1 h before BSO or saline treatment) was based on a previous
report, in which MG-132 selectively inhibited hepatic chymotryptic-
like activity [24]. Pretreatment with MG-132 prior to saline treatment
did not affect the protein expression of rMRP2 during the experimen-
tal period (8 h) as assessed by immunoblot analysis. The rMRP2 pro-
tein level in the pretreated liver was 102±2.4% of the value in saline-
treated control rats (Fig. 3A). However, the BSO-induced reduction
in rMRP2 protein expression was signiﬁcantly suppressed by pre-
treatment with MG-132, yielding an rMRP2 protein level that was
120±9.3% of the value in the saline-treated control (Fig. 3A). On
the other hand, β-actin expression in the total homogenate was not
affected by the experimental conditions (Fig. 3A), demonstrating
that the alterations in rMRP2 protein expression were not due to
changes in total hepatic protein.
3.5. Effect of MG-132 on canalicular membrane localization of rMRP2
and intrahepatic GSH content
As discussed previously [10,22], hepatic GSH content is a major
determinant for rMRP2 localization. Therefore, the effect of MG-132
pretreatment on intrahepatic GSH content and rMRP2 protein expres-
sion in the isolated CrM fraction was investigated. MG-132 did not
affect GSH content in the livers of saline-treated control rats at 8 h
after saline injection (Table 2). MG-132 also did not affect the extent
of the GSH decrease in BSO-treated rats at 8 h after BSO injection
(Table 2). A signiﬁcant reduction in rMRP2 localized at the canalicular
membrane was induced by BSO, irrespective of MG-132 pretreatment
(Fig. 3B). By contrast, the BSO-induced reduction in rMRP2 protein
expression in the liver homogenate was inhibited by MG-132
(Fig. 3A). These data suggest that MG-132 selectively inhibits the
later degradation process of rMRP2 in the proteasome, but not the ini-
tial internalization process induced by GSH decrease per se.
3.6. Effect of BSO treatment on the modiﬁcation of rMRP2 with Ub
Ubiquitination is a well-described post-translational modiﬁcation.
Ubiquitinated proteins are destined for degradation, especially in protea-
somal complexes. This study next investigated the effect of BSO on the
post-translational modiﬁcation of rMRP2 with Ub. Eight hours after BSO
or saline injection, liver lysates were subjected to IP with anti-rMRP2 an-
tiserum, and immunoprecipitates were subjected to immunoblotting
with monoclonal antibodies against MRP2 (M2III6) or mono- and poly-
ubiquitinated conjugates (FK2). The M2III6-immunoreactive unmodiﬁed
rMRP2proteinwas detected as a 175-kDaband in saline-treated (control)
and BSO-treated livers (arrowheads in Fig. 4A and B). The highermolecu-
lar weight bands indicated by arrows were observed with the FK2 anti-
body (Fig. 4A). These bands were also faintly visible with the M2III6
antibody (Fig. 4B). Rabbit serum IgG was used as a negative control
(Fig. 4A) and revealed no immunoprecipitated protein bands.
The overall density of the FK2-immunoreactive bands was signiﬁ-
cantly increased by BSO treatment compared with control saline
treatment; the density was 191.1±8.4% of the control value
(Fig. 4B). On the other hand, the overall level of the rMRP2 proteinTable 2
Effect of MG-132 pretreatment and BSO on intrahepatic GSH
content (nmol/mg protein).
8 h
Control 27.4±3.2
BSO 12.4±2.6**
MG-132/saline 22.1±5.4
MG-132/BSO 10.4±5.5***
The results are given as the mean±S.D. of ﬁve rats. **pb0.01,
***pb0.001 compared with the saline control.was decreased by BSO treatment and was only 52.3±15.2% of the
control value (Fig. 4B), reﬂecting a decrease in its total expression at
8 h after BSO injection (Fig. 1B). Furthermore, the ubiquitinated
rMRP2 to total rMRP2 ratio in the immunoprecipitated specimen
was signiﬁcantly increased by BSO treatment and was 365.5±15.3%
of the control value in saline-treated rats (Fig. 4C).
3.7. Effect of BSO treatment on the modiﬁcation of rMRP2 with SUMO-1
We have previously reported that SUMO-related proteins (Ubc9,
UBA2, and SUMO-1) interacted with the linker region of rat and
humanMRP2 (rat: aa 851–958; human: aa 855–962) in yeast two-hybrid
system [15]. In addition, decrease of rMRP2 protein occurred in Ubc9
knockdown rat hepatoma cells without affecting its mRNA expression
[15]. These results proposed the possibility thatMRP2 expression is reg-
ulated by SUMOylation. Therefore, the effect of BSOwasnext investigat-
ed on themodiﬁcation of rMRP2with SUMO-1 and SUMO-2/3 isoforms.
rMRP2 antiserum-antigen immunoprecipitates from rat liver lysate
were subjected to immunoblotting with a monoclonal antibody against
MRP2 (M2III6) or a polyclonal antibody against either SUMO-1 or
SUMO-2/3. The rMRP2 content in the MRP2 antiserum-antigen immu-
noprecipitate (indicated by arrowhead around 175 kDa in Fig. 5A, top)
was decreased at 8 h following BSO injection to 52.3±15.2% of the
saline-treated control value, which is consistent with the data shown
in Figs. 3A. High molecular weight bands (indicated by arrows in
Fig. 5A, middle) were observed with the SUMO-1 antibody. These
bands were similarly decreased by BSO treatment to 38.3±12.2% of
the control value. However, no immunoreactive bands were detected
with the SUMO-2/3 antibody (Fig. 5A, bottom). Furthermore, the ratio
of SUMOylated to total rMRP2 ratio in the immunoprecipitated speci-
men was signiﬁcantly decreased by BSO treatment to 73.2±11.1% of
the control value (Fig. 5B).
4. Discussion
The expression of efﬂux transporters including rMRP2/hMRP2 is
regulated on a post-transcriptional as well as a transcriptional basis,
with important implications for the pathogenesis of cholestatic syn-
dromes. Post-transcriptional regulation of rMRP2/hMRP2 includes
its rapid translocation from the canalicular membrane of hepatocytes
into the intracellular space by LPS treatment [11,12,25], hyperosmo-
larity [26,27], phalloidin [28], bile acid [29], and oxidative stress
[10,30,13]. However, the fate of rMRP2 after internalization and its
regulatory mechanism, if any, have not yet been elucidated.
The current study demonstrated that BSO treatment induced time-
dependent changes in rMRP2 localization/internalization and protein
degradation in the rat liver. The expression of rMRP2 on the canalicular
membrane was decreased 2 h after BSO treatment without changing
rMRP2 total expression in the homogenate (Fig. 1B), as reported previ-
ously for EA, t-BHP, and LPS treatment [8–11]. At that short time point,
rMRP2 is kept intact in the intracellular compartment, and possibly
recycled back to the membrane surface if GSH is replenished as
reported previously [10]. However, later time point at 8 h after BSO
treatment, rMRP2 total protein expression in the homogenate was sig-
niﬁcantly reduced to 77.2% of the saline-treated control 8 h without
changing rMRP2 mRNA expression. Considering that the half-life of
rMRP2 protein in normal rat hepatocyte is reported to be approximately
29 h [31], rMRP2 protein degradation seems to be accelerated than
usual under sustained GSH decreased condition (~8 h after BSO treat-
ment). Collectively, these results and our previous observation [10] sug-
gest that degradation of rMRP2 on the canalicular membrane surface
follows two subsequent processes: 1) internalization process triggered
by GSH decrease even by for short period [10], and 2) proteasomal deg-
radation process promoted by ubiquitination under sustained GSH de-
crease condition (~8 h after BSO treatment; Fig. 6). Under such
situation, it was observed that ubiquitination and SUMOylation of
Hepatocyte
Bile canalicular lumen
Internalization Proteasome
Degradation
SUMO rMRP2 Ub
(GSH decrease) (GSH repletion)
(Sustained GSH
decrease)
Recycling
rMRP2
rMRP2
Fig. 6. Proposed scheme of rMRP2 degradation during the sustained decrease in GSH content. The results of this study indicate that the degradation pathway of rMRP2 during
sustained decrease in GSH content is composed of two steps: 1) an early phase of internalization, and 2) a late phase of ubiquitin-dependent proteasomal degradation.
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widely accepted concept that poly ubiquitination is a kind of “tag” for
degradation [14] and our recent observation that SUMOylation of
rMRP2 is likely involved in its increased protein expression [15], we
propose the hypothesis that modiﬁcation of rMRP2 by SUMO and Ub
determine the fate of rMRP2 after internalizaion. It was reported that
SUMO competes with Ub for the modiﬁcation of target proteins on
the same amino acid residue in some cases, thus protecting it from
Ub-dependent degradation [32–34]. Such SUMO-mediated protection
has been shown to occur for the glucose transporters GLUT1 and
GLUT4 [35]. Although we did not determine the amino acid residue of
rMRP2 modiﬁed by SUMO and Ub, such scheme is intriguing and con-
sistent with our observation showing mirror image proﬁle of rMRP2
SUMOylation and ubiquitination (Figs. 4 and 5).
Genetic alternations in canalicular transporters (MRP2 and BSEP)
in human patients lead to conjugated hyperbilirubinemia and pro-
gressive liver diseases due to the intrahepatic accumulation of trans-
porter substrates, respectively. For instance, abnormalities in the
intracellular trafﬁcking of MRP2 and BSEP facilitated their proteaso-
mal or lysosomal degradations in patients with DJS and PFIC2, respec-
tively [2–4,36,37]. A recent study indicated that BSEP can be
ubiquitinated, and that this modiﬁcation was associated with acceler-
ated degradation rate of cell-surface-resident BSEP [38]. However, it
remains unclear whether the accelerated degradation of cell-
surface-resident BSEP as a result of ubiquitination stems from the
promotion of endosomal sorting from the cell surface and/or delivery
from the endosomal compartment to the lysosome. In the present
study, it is also not yet known whether the modiﬁcation of rMRP2
with SUMO-1 and Ubiqiutin occurs at the cell surface or in the endo-
somal compartment and its physiological meaning. Interestingly, it
was also notable that SUMOylated rMRP2 was readily detected from
cell homogenate but not from crude membrane under normal condi-
tion (i.e. without BSO treatment) (data not shown). This observation
supports the hypothesis that conjugation reaction of rMRP2 with
SUMO-1 or ubiquitin takes place in the endosomal compartment
rather than on the cell surface. Considering the fact that rMRP2 also
resides in the intracellular pool to some extent [29,13] and sorting
from this pool to the cell surface occurs by several stimuli including
hypo-osmolarity [26,27], blocking rMRP2 in the intracellular pool
from degradation is one of the possible roles of SUMO modiﬁcation.
We have previously reported that rMRP2 internalized in response to
acute oxidative stress can be restored to the canalicular membrane
surface by the replenishment of intrahepatic GSH content [10].
Continuously accelerated internalization of rMRP2 due to sustained
GSH decrease (~8 h after BSO treatment; Table 1) somehow
switches the modiﬁcation of rMRP2 from SUMOylation-dominant toubiquitination-dominant, and ﬁnally Ub-dependent proteasomal
degradation would be occurred (Fig. 6). These modiﬁcations may be
important determinants for the fate of rMRP2 beneath the membrane
surface (proteasomal degradation or recycling to the canalicular
membrane surface).
5. Conclusions
In conclusion, this is the ﬁrst demonstration of proteasomal
degradation of rMRP2 during sustained conditions of reduced intra-
cellular GSH (~8 h after BSO treatment). Modiﬁcation of rMRP2 by
ubiquitination and SUMOylation might be affected and relate to its
proteasomal degradation. This information can be useful to under-
stand the molecular mechanism of the regulation of rMRP2 expres-
sion under various pathological conditions.
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